At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Flovent +1 moredrug
Likely dose
Flovent 1760 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis
In Brief
A Phase 2 clinical trial evaluating Flovent and Placebo for Eosinophilic Esophagitis. Completed, enrolled 42 participants across 4 sites.
Detailed Summary
The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionDec 2011
Study CompletionMar 2012
TodayJul 2026
First PostedJan 24, 2007
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.4 years ago
Interventions
Floventdrug
1760 mcg daily
Placeboother
Placebo